NEW YORK (GenomeWeb News) — Osmetech will use Epidauros Biotechnologies’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing, the companies said today.
 
The diagnostic healthcare company has signed a non-exclusive licensing agreement to use the IP to the genetic variant 2988G>A, which it will use in combination with other variants as predictive markers in its molecular and critical care diagnostic ventures.
 
Financial details were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.